CELL INTELLIGENCE · 肿瘤细胞治疗研究

尽管有新疗法，多发性骨髓瘤的死亡率改善仍在放缓：1990-2023 年按社会人口指数划分的全球差异

Slowing Mortality Improvements in Multiple Myeloma Despite Novel Therapies: Global Disparities by Sociodemographic Index, 1990-2023.

多发性骨髓瘤中的单特异性和双特异性嵌合抗原受体（CAR）T 细胞治疗：系统综述、荟萃分析与荟萃回归

Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression

多发性骨髓瘤药物 III 期临床试验结局的综合综述

Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myeloma.

BCMA 靶向 CAR-T 细胞与 BiTEs 在复发/难治性多发性骨髓瘤中的疗效与安全性比较：干预性研究与真实世界研究的荟萃分析

Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and

老年多发性骨髓瘤患者不断演变中的治疗格局：从四联方案到 T 细胞衔接器与 CAR-T

The Evolving Treatment Landscape for the Elderly Multiple Myeloma Patient: From Quad Regimens to T-Cell Engagers and CAR-T.

多发性骨髓瘤髓外复发表现为肝脏占位性病变，接受 daratumumab、pomalidomide、dexamethasone 和 bendamustine 治疗

Extramedullary relapse of multiple myeloma presenting as space-occupying lesion in liver treated with daratumumab, pomalidomide, dexamethasone and ben

既往接受三种或以上治疗的复发/难治性多发性骨髓瘤患者的真实世界结局：来自 ANZ 骨髓瘤及相关疾病登记处的分析

Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and r

这项回顾性分析证实，澳大利亚 RRMM 患者的结局一致较差。仍然迫切需要提高 CAR-T 等新型治疗在临床试验之外的可及性。

多发性骨髓瘤中的 CAR-T 细胞治疗：B 细胞成熟抗原（BCMA）及更多

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.